Clinical evaluation of Indoramin as the sole agent for the treatment of hypertension

R. Kramer, C. Rosendorff, D. Bloom

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

An open ended clinical trial of Indoramin (WY 21901), a new antihypertensive agent with both α adrenergic blocking and cardio inhibitory properties, was conducted on a group of 27 patients with mild or moderate essential hypertension. Blood pressures, erect and supine, were effectively lowered. In 70% of the patients the mean standing diastolic pressures were well controlled. Heart rate was not significantly lowered. Side effects occurred in 80% of patients, but did not persist in most of them. Severe side effects, necessitating withdrawal of Indoramin, were experienced by 1/3 of the patients. Proteinuria was observed in 3 patients and a slightly elevated serum urea in 1. No other biochemical tests were abnormal.

Original languageEnglish
Pages (from-to)1569-1572
Number of pages4
JournalSouth African Medical Journal
Volume48
Issue number37
StatePublished - 1974
Externally publishedYes

Fingerprint

Dive into the research topics of 'Clinical evaluation of Indoramin as the sole agent for the treatment of hypertension'. Together they form a unique fingerprint.

Cite this